Advanced Prostate Cancer Webcast (2016): Session IV: Revisiting the Index Patients with a New Perspective
Urologists continue to indicate one of the greatest educational needs in treating CRPC patients is the sequencing of agents. With the numerous new treatments now available to urologists to manage the CRPC patient, sequencing and managing the side effects of each treatment have become increasingly important. In order for urologists' role in managing CRPC patients to continue to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.
This course will provide essential information on Advanced Prostate Cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between immunosuppressive agents and other medications. Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.
- Non-Urologist MD
At the end of the course, attendees will be able to:
- Apply the AUA CRPC Guidelines for FDA approved agents in the management of CRPC and optimization of the AUA algorithm for patient clinical benefit
- Evaluate and diagnose CRPC patients and understand the sequencing and combinatorial treatment strategies from both clinical and administrative perspectives
- Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC
- Oversee comorbid conditions and describe their management in the context of CRPC treatment
- Manage both the acute and chronic pain that are inherent in the care of CRPC patients
- Communicate the pertinent end-of-life issues that surround CRPC patients and their families
|Daniel W. Lin, MD||GenProbe||Scientific Study or Trial||No|
|NIH/NCI||Scientific Study or Trial||Yes|
|Department of Defense||Scientific Study or Trial||Yes|
|Veteran's Affairs||Scientific Study or Trial||No|
|Myriad||Consultant or Advisor, Meeting Participant or Lecturer||Yes|
|Genomic Health, Inc.||Scientific Study or Trial||Yes|
|GenomeDx||Scientific Study or Trial||No|
|Astellas||Consultant or Advisor||No|
|Bayer||Consultant or Advisor||Yes|
|David F. Penson, MD||Patient-Centered Outcomes Research Institute||Scientific Study or Trial||Yes|
|Astellas||Scientific Study or Trial||Yes|
|Medivation||Scientific Study or Trial||Yes|
|National Institutes of Health||Consultant or Advisor||Yes|
|US Agency for Healthcare Research and Quality||Consultant or Advisor, Scientific Study or Trial||Yes|
|David I. Quinn, MBBS, PhD, FRACP||Dendreon||Consultant or Advisor, Scientific Study or Trial||Yes|
|Novartis||Consultant or Advisor, Scientific Study or Trial||Yes|
|Medivation||Consultant or Advisor, Scientific Study or Trial||Yes|
|Pfizer||Consultant or Advisor, Scientific Study or Trial||Yes|
|Bayer||Consultant or Advisor, Scientific Study or Trial||Yes|
|Charles J. Ryan, MD||Johnson and Johnson||Consultant or Advisor||Yes|
|Millennium||Consultant or Advisor||Yes|
|Neal D. Shore, MD, FACS||GP Pharma||Consultant or Advisor||No|
|Astellas||Consultant or Advisor||Yes|
|Dendreon||Consultant or Advisor||Yes|
|Medivation||Consultant or Advisor||Yes|
|Janssen||Consultant or Advisor||Yes|
|Bayer||Consultant or Advisor||Yes|
|Myriad||Consultant or Advisor||Yes|
|Genomic Health||Consultant or Advisor||Yes|
|MDxHealth||Consultant or Advisor||Yes|
|Takeda||Consultant or Advisor||Yes|
|Evan Y. Yu, MD||Tokai||Consultant or Advisor||Yes|
|Agensys||Consultant or Advisor, Scientific Study or Trial||Yes|
|Genentech||Meeting Participant or Lecturer, Scientific Study or Trial||Yes|
|Bayer||Scientific Study or Trial||Yes|
|Janssen||Consultant or Advisor||Yes|
|Ferring||Consultant or Advisor||Yes|
|Merck||Scientific Study or Trial||Yes|
|Astellas||Consultant or Advisor, Scientific Study or Trial||Yes|
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation